利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

156 条记录 (耗时 0.05 秒)

    Mitotic kinesin inhibitor
    3.
    发明申请
    Mitotic kinesin inhibitor 失效
    有丝分裂驱动蛋白抑制剂

    公开(公告)号：US20070155804A1

    公开(公告)日：2007-07-05

    申请号：US10553222

    申请日：2004-04-16

    申请人： Chikara Murakata ,  Yoshinori Yamashita ,  Ryuichiro Nakai ,  Kazuhito Akasaka ,  Yoji Ino ,  Kazuhiko Kato ,  Yushi Kitamura

    发明人： Chikara Murakata ,  Yoshinori Yamashita ,  Ryuichiro Nakai ,  Kazuhito Akasaka ,  Yoji Ino ,  Kazuhiko Kato ,  Yushi Kitamura

    IPC分类号： A61K31/433 ,  C07D285/12 ,  C07D417/02

    CPC分类号： C07D285/13 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/5377 ,  C07D285/135

    摘要： A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —C(═W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents —C(═Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.

    摘要翻译： 一种有丝分裂驱动蛋白Eg5抑制剂，其包含由通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为有效成分：[其中R 1表示氢原子等， O 2表示氢原子，-C（-W）R 6（其中W表示氧原子或硫原子，R 6表示 取代或未取代的低级烷基等）等，R 3表示-C（-Z）R 19（其中Z表示氧原子或硫原子， 和R 19表示取代或未取代的低级烷基等）等，R 4表示取代或未取代的低级烷基等，R 5， / SUP>表示取代或未取代的芳基等〕等。

    Thiadiazoline derivative
    7.
    发明授权
    Thiadiazoline derivative 失效
    噻二唑啉衍生物

    公开(公告)号：US07902234B2

    公开(公告)日：2011-03-08

    申请号：US12792448

    申请日：2010-06-02

    申请人： Chikara Murakata ,  Kazuhiko Kato ,  Yoshihisa Ohta ,  Ryuichiro Nakai ,  Yoshinori Yamashita ,  Takeshi Takahashi

    发明人： Chikara Murakata ,  Kazuhiko Kato ,  Yoshihisa Ohta ,  Ryuichiro Nakai ,  Yoshinori Yamashita ,  Takeshi Takahashi

    IPC分类号： A61K31/433 ,  C07D285/125

    CPC分类号： C07D285/135 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/5377

    摘要： (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R6 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(═W)R6 or the like; R3 represents a hydrogen atom, —C(═WA)R6A, or the like)Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

    摘要翻译： （其中R 1和R 4相同或不同，各自表示氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基等; R 6表示取代或未取代的杂环基，取代或未取代的 未取代的芳基等; R 2表示-C（= W）R 6等; R 3表示氢原子，-C（= W）R 6 A等）。 提供包含由上述通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分的抗肿瘤剂。

    Thiadiazoline derivative
    8.
    发明授权
    Thiadiazoline derivative 失效
    噻二唑啉衍生物

    公开(公告)号：US07759371B2

    公开(公告)日：2010-07-20

    申请号：US12098736

    申请日：2008-04-07

    申请人： Chikara Murakata ,  Kazuhiko Kato ,  Yoshihisa Ohta ,  Ryuichiro Nakai ,  Yoshinori Yamashita ,  Takeshi Takahashi

    发明人： Chikara Murakata ,  Kazuhiko Kato ,  Yoshihisa Ohta ,  Ryuichiro Nakai ,  Yoshinori Yamashita ,  Takeshi Takahashi

    IPC分类号： A61K31/433

    CPC分类号： C07D285/135 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/5377

    摘要： (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(═W)R6 or the like; R3 represents a hydrogen atom, —C(═WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

    摘要翻译： （其中R 1和R 4相同或不同，各自表示氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基等; R 5表示取代或未取代的杂环基，取代或未取代的 未取代的芳基等; R 2表示-C（= W）R 6等; R 3表示氢原子，-C（= W）R 6 A等）。抗肿瘤剂包含上述一般所述的噻二唑啉衍生物 提供式（I）或其药理学上可接受的盐作为活性成分。

    Thiadiazoline derivative
    9.
    发明授权
    Thiadiazoline derivative 有权
    噻二唑啉衍生物

    公开(公告)号：US07425636B2

    公开(公告)日：2008-09-16

    申请号：US10497531

    申请日：2002-12-11

    申请人： Chikara Murakata ,  Kazuhiko Kato ,  Yoshihisa Ohta ,  Ryuichiro Nakai ,  Yoshinori Yamashita ,  Takeshi Takahashi

    发明人： Chikara Murakata ,  Kazuhiko Kato ,  Yoshihisa Ohta ,  Ryuichiro Nakai ,  Yoshinori Yamashita ,  Takeshi Takahashi

    IPC分类号： C07D285/135 ,  A61K31/433

    CPC分类号： C07D285/135 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/5377

    摘要： (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(═W)R6 or the like; R3 represents a hydrogen atom, —C(═WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

    摘要翻译： （其中R 1和R 4相同或不同，各自表示氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级链烯基 等等; R 5表示取代或未取代的杂环基，取代或未取代的芳基等; R 2表示-C（-W）R SUP > 6个等等; R 3表示氢原子，-C（-W A）SO 6，或者 提供包含由上述通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为有效成分的抗肿瘤剂。

    Mitotic kinesin inhibitor
    10.
    发明授权
    Mitotic kinesin inhibitor 失效
    有丝分裂驱动蛋白抑制剂

    公开(公告)号：US08318782B2

    公开(公告)日：2012-11-27

    申请号：US13188819

    申请日：2011-07-22

    申请人： Kazuhiko Kato ,  Yushi Kitamura

    发明人： Kazuhiko Kato ,  Yushi Kitamura

    IPC分类号： A61K31/433 ,  C07D285/125

    CPC分类号： C07D285/13 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/5377 ,  C07D285/135

    摘要： A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —C(═W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents —C(═Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.

    摘要翻译： 一种有丝分裂驱动蛋白Eg5抑制剂，其包含由通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分：[其中R 1表示氢原子等，R 2表示氢原子，-C（= W）R6（其中W表示氧原子或硫原子，R6表示取代或未取代的低级烷基等）等，R3表示-C（= Z）R19（其中Z表示氧原子或硫原子 原子，R 19表示取代或未取代的低级烷基等）等，R 4表示取代或未取代的低级烷基等，R 5表示取代或未取代的芳基等〕等。